$TRIL News
Last published 9mo ago
- 9mo agoAMDUETHIHIMYHOOI+3Defiance ETFs Announces Closure of Select FundsGlobeNewswireNEW YORK, Jan. 16, 2026 (GLOBE NEWSWIRE) -- Tidal Financial Group and Defiance ETFs today announced their decision to close and liquidate eight exchange-traded funds listed on the Nasdaq: Defiance Leveraged Long +
- 1y agoTRILDefiance Launches $TRIL – The Trillion Dollar Club ETF: The New "Magnificent 7" of Global MarketsGlobeNewswireNEW YORK, Sept. 30, 2025 (GLOBE NEWSWIRE) -- Defiance ETFs, a leader in innovative and first-mover exchange-traded funds, today announced the launch of the Defiance Trillion Dollar Club Index ETF (NASDAQ:TRIL), the
- 4y agoDMACONCYTRILOncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders and Appoints James T. Parsons to its Board of DirectorsPR NewswireMr. Parsons served as the Chief Financial Officer of Trillium Therapeutics, which was recently acquired by Pfizer Inc. SAN DIEGO and CALGARY, AB, June 17, 2022 /PRNewswire/ -- Oncolytics Biotech® Inc. (NASDAQ:ONCY) (TSX:ONC), today announced the voti
- 5y agoPFETRILTrillium Therapeutics Receives Final Court Order Approving ArrangementGlobeNewswireCAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that
- 5y agoRCKTTBIOTRILFrazier Healthcare Partners Closes Oversubscribed $830 Million Life Sciences Public FundBusiness WireFrazier Healthcare Partners announced today the closing of Frazier Life Sciences Public Fund, L.P., exceeding its target and closing on nearly $830 million in capital commitments in an oversubscribed fundraise. Led by Managing Partner Albert Cha, Gen
- 5y agoFLACISEEKRYSRCKT+4Frazier Healthcare Partners Announces Several Promotions on Life Sciences TeamBusiness WireFrazier Healthcare Partners announced today the promotion of four Life Sciences team members: Jamie Brush, M.D., to General Partner and Portfolio Manager, David Topper to Partner, Capital Markets, Liz Park to Principal, Investor Relations, and Joe Cabra
- 5y agoPFETRILTrillium Securityholders Approve Acquisition by PfizerGlobeNewswireCAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its sec
- 5y agoCXPHRCOPATRILMoore Kuehn Encourages TRIL, OPA, HRC, and CXP Investors to Contact Law FirmGlobeNewswireNEW YORK, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a law firm focusing in securities litigation located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair
- 5y agoABVCCASIQBIOSESN+1Global Liver Cancer Therapeutics Market Size Is Forecasted To Grow To $1.148 Billion By 2026PR NewswirePALM BEACH, Fla., Aug. 24, 2021 /PRNewswire/ -- Recently, approximately 1.2 million new liver cancer cases have been reporting around the world. The increasing intense research and development activities opposing dangerous diseases have developed in the
- 5y agoAXSMCASIORPHTRIL+1Thinking about buying stock in Trillium Therapeutics, Vivos Therapeutics, Axsome Therapeutics, Orphazyme, or CASI Pharmaceuticals?PR NewswireNEW YORK, Aug. 23, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for TRIL, VVOS, AXSM, ORPH, and CASI.
- 5y agoPFETRILPfizer to Acquire Trillium Therapeutics Inc.GlobeNewswireProposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and b
- 5y agoPFETRILTSX:TRILPfizer to Acquire Trillium Therapeutics Inc.Business WireProposed acquisition strengthens Pfizer's category leadership in Oncology with addition of next-generation, investigational immuno-therapeutics for hematological malignancies Expands innovative pipeline, potentially enhancing growth in 2026-2030 and
- 5y agoTRILTrillium Therapeutics Reports Second Quarter 2021 Operating and Financial ResultsGlobeNewswireCAMBRIDGE, Mass., Aug. 13, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the thr
- 5y agoTRILTrillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine in TP53-Mutated Acute Myeloid LeukemiaGlobeNewswireCAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first TP53-mutated ac
- 5y agoTRILTrillium Therapeutics Announces Dosing of First Patient in Phase 1b/2 Study of TTI-622 in Combination With Azacitidine and Venetoclax in TP53-Wild Type Acute Myeloid LeukemiaGlobeNewswireCAMBRIDGE, Mass., July 06, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first acute myeloid l
- 5y agoTRILTrillium Therapeutics Appoints Catherine Mackey, Ph.D., to Its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., June 30, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced the appointme
- 5y agoTRILTrillium Therapeutics Joins Russell 2000® and 3000® IndicesGlobeNewswireCAMBRIDGE, Mass., June 25, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. ("Trillium" or the "Company") (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, joins the broad-market Russel
- 5y agoTRILTrillium Announces Voting Results From the Annual General and Special Meeting of ShareholdersGlobeNewswireCAMBRIDGE, Mass., June 09, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL) (the "Corporation"), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced the voting results from its A
- 5y agoIMGNSBFMSRNETRIL+1Novel Anti-Cancer Drugs Permeate the MarketplacePR NewswireNEW YORK, May 25, 2021 /PRNewswire/ -- The cancer therapeutics market is one of the largest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8 million people were diagnosed with cancer in the United States in
- 5y agoATNXMRKRONCYSEEL+1Increased R&D Activities Have Fueled Growth and Promise for Pancreatic Cancer TreatmentPR NewswirePALM BEACH, Fla., May 20, 2021 /PRNewswire/ -- Sadly, for patients, the pancreatic cancer market has been steadily rising over the past several years and will most likely continue to grow over the next couple of years. Revenues will increase but so wil
- 5y agoTRILTrillium Therapeutics Reports First Quarter 2021 Operating and Financial ResultsGlobeNewswireCAMBRIDGE, Mass., May 07, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today reported financial and operating results for the three
- 5y agoCSTMELYSGSXNAVI+1Thinking about buying stock in GSX Techedu, Elys Game Technology, Navient Corp, Constellium SE, or Trillium Therapeutics?PR NewswireNEW YORK, April 28, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GSX, ELYS, NAVI, CSTM, and TRIL.
- 5y agoTRILTrillium Therapeutics Announces Dosing of First Patient in Phase 1b Study of TTI-622 in Combination With Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple MyelomaGlobeNewswireCAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it has dosed the first multiple myelo
- 5y agoTRILTrillium Therapeutics Provides Data Update, Announces Phase 1b/2 Program Priorities Across Hematologic Malignancies and Solid Tumors, and Reports Governance ChangesGlobeNewswireTTI-622 monotherapy shows 33% objective response rate (ORR) in relapsed/refractory (R/R) lymphomas at 0.8-18 mg/kg doses, including 3 new responses (1 Complete Response (CR) + 2 Partial Responses (PRs)) since last data disclosure; TTI-621 monotherapy s
- 5y agoTRILTrillium Therapeutics to Host Virtual R&D Day for Investors on April 28, 2021GlobeNewswireCAMBRIDGE, Mass., April 22, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (TSX:TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that it will host its virtual R&D Day for
- 5y agoAGENLPTXTRILVSTMInnovative Diagnostic Methods Remains Vital in the Fight Against CancerPR NewswireThe cancer treatment market is one of the biggest segments of the biotechnology industry. According to the National Cancer Institute, roughly 1.8...
- 5y agoTRILTrillium Therapeutics Reports Annual Operating and Financial Results and Sets Date for R&D DayGlobeNewswireWide-ranging transformation program completedR&D Day scheduled for April 28, 2021, to provide data updates, and announce strategic priorities and clinical development plan going forward$291.2...
- 5y agoCRDFTRILSURFCTMXContinued Research Grants New Options in Cancer TreatmentPR NewswireThe growing prevalence of cancer all over the globe is a major obstacle to overcome. In 2020, an estimated 1,806,590 new cases of cancer were...
- 5y agoMRNABDSIVRTXTRILAn Aging Population is Increasing the Need for Novel TreatmentsPR NewswireWith the onset of a world health crisis, our seniors are at a greater risk than they were a decade ago. In addition, the growing senior population...
- 5y agoPFEEPIXTRILFIXXPfizer Invests $120 Million in Biotechnology Innovation Through the Pfizer Breakthrough Growth InitiativeBusiness WireNEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that, during the second half of 2020, it invested a total of $120 million in four clinical-stage biotech companies as part of the Pfizer Breakthrough Growth Initiative (PBGI). Through PBGI, Pfizer is investing up to $500 million in biotechnology companies, providing funding and access to Pfizer’s scientific expertise to help ensure ...
- 5y agoPHATPASGRCKTTRILFrazier Healthcare Partners Announces Multiple Promotions on its Life Sciences TeamBusiness WireMENLO PARK, Calif.--(BUSINESS WIRE)--Frazier Healthcare Partners announced the promotion of several members on its Life Sciences team: Aditya Kohli to Venture Partner, Anna Chen to Vice President, and Max Nowicki to Senior Associate.
- 5y agoTRILTrillium Therapeutics Presented Clinical Data at the 62nd ASH Annual Meeting and Provides Guidance for 2021GlobeNewswireCAMBRIDGE, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 5y agoTRILTrillium Therapeutics to Present Clinical Data at the 62nd American Society of Hematology Annual MeetingGlobeNewswireCAMBRIDGE, Mass., Nov. 25, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of...
- 5y agoTRILTrillium Therapeutics Reports Third Quarter 2020 Financial and Operating ResultsGlobeNewswireCAMBRIDGE, Ma., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Therapeutics Appoints Paolo Pucci to Its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Therapeutics Appoints Dr. Ingmar Bruns as Chief Medical OfficerGlobeNewswireCAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Therapeutics Announces Formation of Scientific Advisory BoardGlobeNewswireCAMBRIDGE, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Therapeutics Receives Notices of Allowance From U.S. Patent and Trademark OfficeGlobeNewswireAllowance received for the use of SIRPaFc to treat both hematologic and solid tumors (method of use patent)Allowance received for the TTI-622 composition of matter patent CAMBRIDGE, Mass., Oct. 05,...
- 6y agoTRILTrillium Therapeutics Appoints Michael Kamarck, Ph.D., to Its Board of DirectorsGlobeNewswireCAMBRIDGE, Mass., Sept. 18, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Closes US$150 Million Public Offering of Common SharesGlobeNewswireCAMBRIDGE, Mass., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Announces Pricing of US$130 Million Public Offering of Common SharesGlobeNewswireCAMBRIDGE, Mass., Sept. 10, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Announces Proposed Public Offering of Common SharesGlobeNewswireCAMBRIDGE, Mass., Sept. 09, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Therapeutics Announces $25 Million Equity Investment From Pfizer Inc.GlobeNewswirePfizer invests $25 million in Trillium common shares at $10.88 per shareJeff Settleman, PhD, Pfizer’s Chief Scientific Officer for Oncology Research & Development, to join Trillium Scientific...
- 6y agoTRILTrillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation StudiesGlobeNewswireTTI-622 (SIRPa-IgG4 Fc) completed 8 mg/kg safety assessment in the ongoing dose escalation study in relapsed/refractory lymphoma; now escalating to 12 mg/kg dose level.TTI-622 monotherapy shows 6/18...
- 6y agoTRILTrillium Therapeutics Reports Second Quarter 2020 Financial and Operating ResultsGlobeNewswireTTI-621 study has progressed to the 2.0 mg/kg dosing levelTTI-622 showing early evidence of monotherapy activity$130.8 million of cash and investments as of June 30, 2020 CAMBRIDGE, Mass., Aug. ...
- 6y agoTRILTrillium Therapeutics Provides Update On Phase 1 Study Of TTI-621 And Dose Escalation To 2.0 MG/KG LevelGlobeNewswireCAMBRIDGE, Mass., July 30, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX:TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Announces Voting Results From the Annual and Special Meeting of ShareholdersGlobeNewswireCAMBRIDGE, Mass., July 06, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL) (the “Corporation”), a clinical stage immuno-oncology company developing innovative therapies for...
- 6y agoTRILTrillium Therapeutics Reports First Quarter 2020 Financial and Operating ResultsGlobeNewswireCAMBRIDGE, Mass., May 15, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Therapeutics to Present Data on CD47 Blocker TTI-622 in Advanced Relapsed or Refractory Lymphoma at the ASCO20 Virtual Scientific ProgramGlobeNewswireCAMBRIDGE, Mass., May 13, 2020 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative...
- 6y agoTRILTrillium Therapeutics Responds to Market ActivityGlobeNewswireCAMBRIDGE, Mass., Feb. 28, 2020 (GLOBE NEWSWIRE) -- At the request of IIROC ("Investment Industry Regulatory Organization of Canada"), Trillium Therapeutics Inc. (the “Company”) (NASDAQ/TSX: TRIL)...